A Placebo-Controlled, Cross-Over Trial of Aripiprazole
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of
the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated
patients with schizophrenia or schizoaffective disorder. The advantage of the crossover
design is that each subject will act as their own control and fewer subjects will be required
than a between-group design.